论文信息 - Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis. - 字舞流文

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis.

F. Fostira | E. Fountzilas | V. Kotoula

[1] A. Duval,et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status , 2019, JAMA oncology.

[2] P. Keegan,et al. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.

[3] M. D. James,et al. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial , 2015, Journal of Clinical Pathology.

[4] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[5] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.